The estimated Net Worth of Willard H Dere is at least $2.2 million dollars as of 26 June 2020. Willard Dere owns over 4,430 units of Biomarin Pharmaceutical stock worth over $1,126,726 and over the last 20 years he sold BMRN stock worth over $619,476. In addition, he makes $454,270 as Independent Director at Biomarin Pharmaceutical.
Willard has made over 3 trades of the Biomarin Pharmaceutical stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 4,430 units of BMRN stock worth $547,592 on 26 June 2020.
The largest trade he's ever made was selling 4,430 units of Biomarin Pharmaceutical stock on 26 June 2020 worth over $547,592. On average, Willard trades about 149 units every 8 days since 2004. As of 26 June 2020 he still owns at least 13,290 units of Biomarin Pharmaceutical stock.
You can see the complete history of Willard Dere stock trades at the bottom of the page.
Dr. Willard H. Dere, M.D. is Independent Director of the Company. He joined our Board in July 2016. Since November 2014, he has served as the Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical & Translational Science at the University of Utah Health Sciences Center. He also serves as the Interim Associate Vice President for Research of Health Sciences, and Interim Vice-Dean for Research of the School of Medicine. Prior to re-joining academia in November 2014, Dr. Dere was in the biopharmaceutical industry for 25 years. From 2003 until his retirement in 2014, Dr. Dere held multiple roles at Amgen, Inc., a biotechnology company, including serving as head of global development and either the international or corporate chief medical officer from December 2004 to October 2014. He began his career at Eli Lilly in 1989, and held a number of different global roles in clinical pharmacology, regulatory affairs, and both early-stage translational, and late-stage clinical research. He serves on the boards of three public biopharmaceutical companies: Mersana Therapeutics, Inc., Radius Health, Inc., and Seres Therapeutics, Inc. and concluded his service to Ocera Therapeutics, Inc. in December 2017. Since 2014, he has served on the scientific advisory board of the California Institute of Regenerative Medicine. Dr. Dere received a B.A. and an M.D. from the University of California, Davis. He trained in internal medicine at the University of Utah and in endocrinology/ metabolism at the University of California at San Francisco.
As the Independent Director of Biomarin Pharmaceutical, the total compensation of Willard Dere at Biomarin Pharmaceutical is $454,270. There are 16 executives at Biomarin Pharmaceutical getting paid more, with Jean-Jacques Bienaime having the highest compensation of $18,405,900.
Willard Dere is 66, he's been the Independent Director of Biomarin Pharmaceutical since 2016. There are 6 older and 16 younger executives at Biomarin Pharmaceutical. The oldest executive at Biomarin Pharmaceutical Inc. is Alan Lewis, 74, who is the Independent Director.
Willard's mailing address filed with the SEC is C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Over the last 21 years, insiders at Biomarin Pharmaceutical have traded over $153,109,113 worth of Biomarin Pharmaceutical stock and bought 151,118 units worth $2,557,509 . The most active insiders traders include Jean Jacques Bienaime, Mark J Enyedy et Kathryn E Falberg. On average, Biomarin Pharmaceutical executives and independent directors trade stock every 8 days with the average trade being worth of $912,996. The most recent stock trade was executed by Erin Burkhart on 13 August 2024, trading 714 units of BMRN stock currently worth $64,260.
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
Biomarin Pharmaceutical executives and other stock owners filed with the SEC include: